Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
KROS Keros Therapeutics, Inc.	$435M	$1.96 Million 0.0% of portfolio	146,600	Q2 2025 New
EDIT Editas Medicine, Inc.	$183M	$1.95 Million 0.0% of portfolio	888,400	Q2 2025 Reduced 14.0%
ALLO Allogene Therapeutics, Inc.	$178M	$1.89 Million 0.0% of portfolio	1,670,012	Q2 2025 Added 7.28%
INZY Inozyme Pharma, Inc.	$161M	$1.88 Million 0.0% of portfolio	470,500	Q2 2025 Reduced 16.65%
CRMD Cor Medix Inc.	$462M	$1.88 Million 0.0% of portfolio	152,200	Q2 2025 New
ANNX Annexon, Inc.	$140M	$1.87 Million 0.0% of portfolio	777,900	Q2 2025 Reduced 33.08%
CDXS Codexis, Inc.	$118M	$1.84 Million 0.0% of portfolio	755,486	Q2 2025 Added 16.09%
LCTX Lineage Cell Therapeutics, Inc.	$306M	$1.79 Million 0.0% of portfolio	1,972,335	Q2 2025 Reduced 13.92%
ZNTL Zentalis Pharmaceuticals, Inc.	$79.8M	$1.77 Million 0.0% of portfolio	1,529,553	Q2 2025 Added 85.17%
ALEC Alector, Inc.	$112M	$1.76 Million 0.0% of portfolio	1,254,850	Q2 2025 Added 21.38%
ABEO Abeona Therapeutics Inc.	$24.8M	$1.7 Million 0.0% of portfolio	299,937	Q2 2025 Added 128.02%
ACIU Ac Immune Sa	$290M	$1.68 Million 0.0% of portfolio	828,321	Q2 2025 Added 3.09%
LRMR Larimar Therapeutics, Inc.	$157M	$1.62 Million 0.0% of portfolio	561,742	Q2 2025 Reduced 42.38%
MGNX Macrogenics Inc	$91.6M	$1.61 Million 0.0% of portfolio	1,326,494	Q2 2025 Added 15.12%
CCCC C4 Therapeutics, Inc.	$116M	$1.56 Million 0.0% of portfolio	1,093,188	Q2 2025 Added 409.64%
ATXS Astria Therapeutics, Inc.	$190M	$1.55 Million 0.0% of portfolio	289,778	Q2 2025 Added 61.74%
ATOS Atossa Therapeutics, Inc.	$104M	$1.5 Million 0.0% of portfolio	1,812,251	Q2 2025 Reduced 2.31%
AKRO Akero Therapeutics, Inc.	$2.51B	$1.49 Million 0.0% of portfolio	28,000	Q2 2025 Reduced 85.93%
REPL Replimune Group, Inc.	$450M	$1.42 Million 0.0% of portfolio	153,089	Q2 2025 Reduced 2.01%
CSBR Champions Oncology, Inc.	$94.3M	$1.33 Million 0.0% of portfolio	181,039	Q2 2025 Added 19.07%
TYRA Tyra Biosciences, Inc.	$611M	$1.29 Million 0.0% of portfolio	135,100	Q2 2025 Added 162.84%
VYGR Voyager Therapeutics, Inc.	$164M	$1.22 Million 0.0% of portfolio	392,100	Q2 2025 Added 226.21%
NKTX Nkarta, Inc.	$95.9M	$1.16 Million 0.0% of portfolio	696,372	Q2 2025 Reduced 14.19%
OMER Omeros Corp	$437M	$1.15 Million 0.0% of portfolio	382,700	Q2 2025 New
TCRX T Scan Therapeutics, Inc.	$23.5M	$1.15 Million 0.0% of portfolio	792,056	Q2 2025 Added 366.72%
IPSC Century Therapeutics, Inc.	$31.2M	$1.13 Million 0.0% of portfolio	2,022,500	Q2 2025 Added 70.63%
RCKT Rocket Pharmaceuticals, Inc.	$247M	$1.13 Million 0.0% of portfolio	461,374	Q2 2025 Added 36.31%
TNYA Tenaya Therapeutics, Inc.	$60M	$1.12 Million 0.0% of portfolio	1,843,879	Q2 2025 Added 19.6%
ICCC Immucell Corp	$48.5M	$1.11 Million 0.0% of portfolio	159,989	Q2 2025 Added 19.4%
LIFE A Tyr Pharma Inc	$53.2M	$964,000 0.0% of portfolio	518,355	Q2 2025 Added 8.0%
ERAS Erasca, Inc.	$288M	$942,000 0.0% of portfolio	742,500	Q2 2025 Reduced 22.37%
IMNM Immunome Inc.	$212M	$924,000 0.0% of portfolio	99,372	Q2 2025 Reduced 14.33%
DSGN Design Therapeutics, Inc.	$433M	$902,000 0.0% of portfolio	267,800	Q2 2025 Added 1.06%
VKTX Viking Therapeutics, Inc.	$3.03B	$866,000 0.0% of portfolio	32,700	Q2 2025 Reduced 90.02%
MRSN Mersana Therapeutics, Inc.	$824M	$855,000 0.0% of portfolio	2,850,194	Q2 2025 Added 239.34%
CADL Candel Therapeutics, Inc.	$145M	$827,000 0.0% of portfolio	163,600	Q2 2025 New
GBIO Generation Bio Co.	$325M	$825,000 0.0% of portfolio	2,580,780	Q2 2025 Added 37.23%
AURA Aura Biosciences, Inc.	$163M	$823,000 0.0% of portfolio	131,548	Q2 2025 Added 27.35%
AADI Aadi Bioscience, Inc.	$35.9M	$783,000 0.0% of portfolio	458,222	Q2 2025 Reduced 0.84%
VOR Vor Biopharma Inc.	$373M	$758,000 0.0% of portfolio	468,112	Q2 2025 Reduced 33.26%
YMAB Y M Abs Therapeutics, Inc.	$376M	$740,000 0.0% of portfolio	164,100	Q2 2025 Reduced 36.07%
RPTX Repare Therapeutics Inc.	$72.6M	$726,000 0.0% of portfolio	522,859	Q2 2025 Added 75.07%
ACET Adicet Bio, Inc.	$26M	$703,000 0.0% of portfolio	1,153,816	Q2 2025 Added 42.32%
VRCA Verrica Pharmaceuticals Inc.	$327M	$693,000 0.0% of portfolio	87,200	Q2 2025 New
OVID Ovid Therapeutics Inc.	$94.4M	$691,000 0.0% of portfolio	2,095,309	Q2 2025 Added 104.66%
CRBU Caribou Biosciences, Inc.	$125M	$670,000 0.0% of portfolio	532,121	Q2 2025 New
CRVS Corvus Pharmaceuticals, Inc.	$380M	$660,000 0.0% of portfolio	165,188	Q2 2025 Reduced 37.66%
STRO Sutro Biopharma, Inc.	$41.7M	$648,000 0.0% of portfolio	913,197	Q2 2025 Added 5.09%
CMPX Compass Therapeutics, Inc.	$451M	$583,000 0.0% of portfolio	224,600	Q2 2025 Reduced 30.14%
ADPT Adaptive Biotechnologies Corp	$2.08B	$581,000 0.0% of portfolio	49,900	Q2 2025 Reduced 52.87%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account